Hepcinat LP  is a direct-acting antiviral drug containing sofosbuvir and ledipasvir. This is a generic of the first combined medication for the treatment of chronic hepatitis C Harvoni. Adding Ledipasvir to Sofosbuvir made it possible to “get away” from interferon regimens and achieve a positive result in patients with the first HCV genotype that was difficult to treat

 

 

Our Privacy Notice has been updated to explain how we use cookies, which you accept by continuing to use this website. To withdraw your consent, see Your Choices.